<html>
<body bgcolor="#fff" >
<table align="center" border="1" style="width: 90%; height: 60%;">
<tbody>
<tr>
<td height="420" valign="top" bgcolor="#CCCCCC" style="padding-top:
10px;">
<table align="center" border="1" style="width: 98%;">
<tbody>
<tr bgcolor="#6f7071">
<td height="77">
<p align="left " style="font-family: 'Georgia',Helvetica; padding: 10px 0px
5px 0px; margin: 0px; color: #e4e5e8; font-size: 24px; font-weight: normal;
letter-spacing: -1px; display: block; border-bottom: dashed 1px
#ccc;"><span style="font-size: large;">Nuvilex Inc.'s (NVLX)</span></p>
<p style="font-size: '18px';" color="020202" align="center"><strong>
<em><strong><b>Nuvilex</b><b>, Inc., John-son & Johnson, and
Med_tronic,
Inc., </b><b>All </b><b>Inventing </b><b> Type of
Artificial Pancreas for Diabetics</b></strong></em></strong></p>
</td>
</tr>
<tr bgcolor="#fff">
<td height="202">
<p align="left"><span><br />While Medtronic, Inc. (NYSE: MDT) and John-son
& John_son</span><b> </b><span>(NYSE: J-N-J) are inventing devices
that can basically act as a type of “artificial
pancreas,” </span><b>Nuvilex</b><b>,
Inc.</b><span> (</span><b>NVLX</b><span>) unique cell encapsulation
technology has shown they also can create a type of
“</span><b>artificial pancreas</b><span>” in preclinical
diabetes studies. Their approaches couldn’t be more different;
however, all three companies are sure that developing an artificial
pancreas offers diabetics the finest res_ult to independently monitor their
blo_od sugar levels, and in exchange, supply them with insulin when
desired.</span></p>
<p>As the two N-Y-S-E-traded organizations turn to medical devices act as
their brand of artificial pancreas, the minor, Silver Spring,
Maryland-based biotech, Nuvilex, is turning to a much more minor and
different option – transplanted living, insulin-producing cells
enclosed in capsules approximately the dimension of the head of a pin, that
create a bundle and act as a miniature cell factory that makes insulin upon
demand inside the diabetics physique.</p>
<p align="justify"><strong><em> </em></strong><span>701 Fifth Ave.,
42nd Fl., Seattle, Washington 98104-5119 USA<br /> </span></p>
</td>
</tr>
</tbody>
</table>
<table align="center" border="1" style="width: 98%;">
<tbody>
<tr>
<td bgcolor="#c8cbcc">
<p align="center" style="font-family: 'Verdana'; font-size: 8px; color:
#0000; text-align: justify;"><span style="font-family: Georgia, helvetica,
sans-serif; font-size: x-small;">The use of research materials circulated
by the auth.or is done at your own risk. You are encouraged to do your own
research before making any investment decision in regards to the secu rity
discussed herein. The author has not been rewarded by any entity in
connection with the distribution of these materials. You should presume
that as of the date of this report or letter, the author, possibly along
with or through our owners, affiliates, employees and/or consultants,
(cooperatively referred to as the author) has a position in all company
shares (and/or options of the shares) covered herein that is consistent
with the position set forth in our report. In connection with NVLX, the
author has taken a long position. Following the disbursement of any report
or letter, the author intends to continue engaging in trnsactns in the secu
rity covered herein, and we may be long, short, and/or neutral at any time
hereafter regardless of our initial position and we preserve the right to
procure or trade all or part of our position at any time without notice.
This practice could end in our trading securities at any time before,
during, and/or after the disbursement of this report.<br /> <br /> <a
href="http://support.bifurcadaregardedbi.net/unsubscribe.php?M=6588707&C=0a89a74737fe0ab850bde605efc11be4&L=54&N=1867">Unsubscribe
me from this list</a></span></p>
</td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
<img
src="http://support.bifurcadaregardedbi.net/open.php?M=6588707&L=54&N=1867&F=H&image=.jpg"
height="1" width="10"></body>
</html>